Inhibitors of MYH7B and uses thereof
The present invention provides nucleic acid inhibitors of MYH7B and compositions thereof. The present invention also provides methods of treating or preventing a cardiac disorder such as cardiac hypertrophy, myocardial infarction, or heart failure in a subject by administering to the subject an inhibitor of MYH7B. The present invention further provides methods of modulating the activity or expression of β-MHC in cardiac cells of a subject by administering to the subject an inhibitor of MYH7B.
1. An antisense oligonucleotide inhibitor of MYH7B containing at least one modified nucleotide, wherein the antisense oligonucleotide is 8 to 18 nucleotides and wherein the sequence of the antisense oligonucleotide is completely complementary to a sequence of SEQ ID NO: 6 from nucleotides 4300-4317, nucleotides 4302-4315, or nucleotides 4318-4331.
2. The antisense oligonucleotide inhibitor of claim 1 , wherein the antisense oligonucleotide is 14 nucleotides and the sequence of the antisense oligonucleotide is completely complementary to a sequence of SEQ ID NO: 6 from nucleotides 4300-4317.
3. The antisense oligonucleotide inhibitor of claim 1 , wherein the antisense oligonucleotide is 14 nucleotides and the sequence of the antisense oligonucleotide is completely complementary to the sequence of SEQ ID NO: 6 from nucleotides 4302-4315.
4. The antisense oligonucleotide inhibitor of claim 1 , wherein the antisense oligonucleotide is 14 nucleotides and the sequence of the antisense oligonucleotide is completely complementary to the sequence of SEQ ID NO: 6 from nucleotides 4318-4331.
5. The antisense oligonucleotide inhibitor of claim 1 , wherein said modified nucleotide includes a sugar, base, or a backbone modification.
6. The antisense oligonucleotide inhibitor of claim 5 , wherein the sugar modification is selected from the group consisting of 2′-O, 4′-C methylene bridge, 2′-O, 4′-C ethylene bridge, 2′-CH 2 —NH—CH 2 -4′ bridge, 2′-deoxy, 2′-O-alkyl, and 2′-halo modifications.
7. The antisense oligonucleotide inhibitor of claim 5 , wherein the backbone modification is a phosphorothioate linkage.
8. The antisense oligonucleotide inhibitor of claim 7 , wherein said antisense oligonucleotide contains two or more phosphorothioate linkages.
9. The antisense oligonucleotide inhibitor of claim 8 , wherein said antisense oligonucleotide is fully phosphorothioate linked.
10. The antisense oligonucleotide inhibitor of claim 1 , wherein said modified nucleotide is a locked nucleotide.
11. The antisense oligonucleotide inhibitor of claim 1 , wherein said antisense oligonucleotide contains one to six locked nucleotides.
12. The antisense oligonucleotide inhibitor of claim 1 , wherein said antisense oligonucleotide contains at least three locked nucleotides at the 5′ end.
13. The antisense oligonucleotide inhibitor of claim 12 , wherein the at least three locked nucleotides at the 5′ end are ribonucleotides.
14. The antisense oligonucleotide inhibitor of claim 1 , wherein said antisense oligonucleotide contains at least three locked nucleotides at the 3′ end.
15. The antisense oligonucleotide inhibitor of claim 14 , wherein the at least three locked nucleotides at the 3′ end are ribonucleotides.
16. The antisense oligonucleotide inhibitor of claim 1 , wherein said antisense oligonucleotide contains at least one deoxyribonucleotide.
17. The antisense oligonucleotide inhibitor of claim 16 , wherein said antisense oligonucleotide contains two to eight deoxyribonucleotides.
18. The antisense oligonucleotide inhibitor of claim 1 , wherein said modified nucleotide is 5′-methyl cytidine.
19. A pharmaceutical composition comprising the antisense oligonucleotide inhibitor of MYH7B of claim 1 and a pharmaceutically acceptable excipient.
20. The pharmaceutical composition of claim 19 , further comprising a second therapeutic agent, wherein the second therapeutic agent is an antisense oligonucleotide inhibitor of miR-208a, miR-208b, miR-499, miR-15a, miR-15b, miR-16, miR-195, or a mixture thereof.
21. An antisense oligonucleotide inhibitor of MYH7B containing at least one modified nucleotide, and wherein said antisense oligonucleotide comprises a sequence selected from Tables 1-5.
22. The antisense oligonucleotide inhibitor of claim 21 , wherein said antisense oligonucleotide comprises the sequence of 5′-lTslTslGsdAsdTsdCsdTsdTsdGsdGsdCslCslTslC-3′ (SEQ ID NO: 146) or 5′ -lCslTslGsdCsdAsdGsdCsdTsdCsdCsdTslCslCslA-3′ (SEQ ID NO: 148).
23. The antisense oligonucleotide inhibitor of claim 21 , wherein said antisense oligonucleotide comprises the sequence of 5′-lCslCslAsdGsdGsdAsdGsmdCsmdCsdTsdAslTslTslC-3′ (SEQ ID NO: 494).
24. The antisense oligonucleotide inhibitor of claim 21 , wherein said antisense oligonucleotide comprises the sequence of 5′-lGslTslTsmdCsdAsmdCsdTsmdCsdAsmdCsdAslTslCslC-3′ (SEQ ID NO: 188).
25. The antisense oligonucleotide inhibitor of claim 21 , wherein said antisense oligonucleotide comprises the sequence of 5′-lAslGslTsdTsmdCsdAsmdCsdTsmdCsdAsmdCslAslTslC-3′ (SEQ ID NO: 190).
26. The antisense oligonucleotide inhibitor of claim 21 , wherein said antisense oligonucleotide comprises the sequence of 5′-lAslGslTsdTsdAsdTsmdCsdAsdTsdTsmdCslCslTslC-3′ (SEQ ID NO: 370).
27. The antisense oligonucleotide inhibitor of claim 21 , wherein said antisense oligonucleotide comprises the sequence of 5′-lCslTslTsdAsdGsmdCsdTsdGsdAsdTsmdCslCslTslC-3′ (SEQ ID NO: 568).
28. A pharmaceutical composition comprising the antisense oligonucleotide inhibitor of MYH7B of claim 21 and a pharmaceutically acceptable excipient.
29. The pharmaceutical composition of claim 28 , further comprising a second therapeutic agent, wherein the second therapeutic agent is an antisense oligonucleotide inhibitor of miR-208a, miR-208b, miR-499, miR-15a, miR-15b, miR-16, miR-195, or a mixture thereof.